The Latin America, Middle East and Africa Non-steroidal Anti-inflammatory Drugs Market would witness market growth of 8.3% CAGR during the forecast period (2022-2028).
The analgesic impact of non NSAIDs are equivalent to those of first opioid dosages in acute situations. While greater doses do mediate anti-inflammatory benefits, unlike opioids, NSAIDs have a maximum dose above that no additional pain reduction occurs. Non-aspirin NSAIDs are similar to aspirin in lowering joint swelling, pain, and morning stiffness as well as in enhancing strength and mobility, according to clinical investigations in individuals with arthritis. Diclofenac, which is a nonselective NSAID, and celecoxib, a COX-2-specific NSAID, both showed superior pain and stiffness alleviation in randomized, double-blind, controlled studies using acetaminophen as the comparison.
Inflammation has been recognized as a key player in the aetiology of OA and OA-related pain in an increasing body of research. To variable degrees, inflammatory cytokines & proteases are involved in the breakdown of joints and aggravation of nociception. Individual variations in the level of inflammation and vulnerability to nociception sensitization might, at least in part, account for why many patients with radiographically mild illness experience considerable pain while others with more severe joint degeneration experience less discomfort. Because of this, using analgesics with no anti-inflammatory effects in the joints, like acetaminophen, would only relieve pain without having any clinically useful anti-inflammatory effects.
There are many people across this region who are facing severe chronic pain due to various diseases and hence, doctors are increasingly suggesting NSAIDs. Along with that, there is surge in the investment done by governments in the healthcare sector, which would fuel the product demand.
Disorders of the musculoskeletal system are prevalent in the general population. One of the main reasons of disability in the UAE is lower back pain, which is also a primary source of disability. Few researches have examined the frequency of rheumatic illnesses in the general population in the Middle East. Several of these studies have discussed the frequency of various musculoskeletal conditions in the general population.
The Brazil market dominated the LAMEA Non-steroidal Anti-inflammatory Drugs Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $512.3 Million by 2028. The Argentina market is experiencing a CAGR of 8.9% during (2022 - 2028). Additionally, The UAE market would display a CAGR of 8% during (2022 - 2028).
Based on Route of Administration, the market is segmented into Oral, Topical and Others. Based on Distribution Channel, the market is segmented into Retail Pharmacy, Hospital Pharmacy and Online Pharmacy. Based on Route of Disease Indication, the market is segmented into Arthritis, Migraine, Ophthalmic Diseases and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
Free Valuable Insights: The Global Non-steroidal Anti-inflammatory Drugs Market is Predict to reach $25.5 Billion by 2028, at a CAGR of 5.7%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Dr. Reddy’s Laboratories Ltd., Pfizer, Inc., GlaxoSmithKline PLC, Bayer AG, Teva Pharmaceuticals Industries Ltd., Eli Lilly And Company, Sanofi S.A., AstraZeneca PLC, Viatris, Inc., and Merck & Co., Inc.
By Route of Administration
By Distribution Channel
By Disease Indication
By Country
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
